603087 甘李药业
已收盘 10-08 15:00:00
资讯
新帖
简况
甘李药业：9月29日陈伟、邹蓉、都凯、宋维强减持股份合计3.5万股
证券之星 · 09-30
甘李药业：9月29日陈伟、邹蓉、都凯、宋维强减持股份合计3.5万股
甘李药业（603087）9月28日主力资金净卖出529.80万元
证券之星 · 09-29
甘李药业（603087）9月28日主力资金净卖出529.80万元
甘李药业：9月24日董事宋维强减持股份合计3万股
证券之星 · 09-28
甘李药业：9月24日董事宋维强减持股份合计3万股
甘李药业（603087）9月23日主力资金净买入4477.43万元
证券之星 · 09-24
甘李药业（603087）9月23日主力资金净买入4477.43万元
9月23日甘李药业涨5.47%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 09-23
9月23日甘李药业涨5.47%，招商国证生物医药指数(LOF)C基金重仓该股
甘李药业涨5.47%，国金证券四周前给出“买入”评级
证券之星 · 09-23
甘李药业涨5.47%，国金证券四周前给出“买入”评级
甘李药业：9月17日高级管理人员李智减持股份合计2万股
证券之星 · 09-21
甘李药业：9月17日高级管理人员李智减持股份合计2万股
甘李药业(603087.SH)：在研药品GLR1075注射液获药物临床试验批准
智通财经 · 09-18
甘李药业(603087.SH)：在研药品GLR1075注射液获药物临床试验批准
甘李药业：股价波动受多种因素影响
证券之星 · 09-17
甘李药业：股价波动受多种因素影响
甘李药业：公司产品在泰国获得上市批准
证券之星 · 09-17
甘李药业：公司产品在泰国获得上市批准
甘李药业：本次海外50多亿的订单为协议全周期潜在里程碑与销售分成总额
证券之星 · 09-17
甘李药业：本次海外50多亿的订单为协议全周期潜在里程碑与销售分成总额
每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药
证券之星 · 09-13
每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药
甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药
美股速递 · 09-09
甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药
甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%
证券之星 · 09-08
甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%
甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药
智通财经 · 09-07
甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药
甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股
证券之星 · 09-04
甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股
甘李药业：高管减持潮背后，财务与转型双重考验显现
新浪证券 · 09-04
甘李药业：高管减持潮背后，财务与转型双重考验显现
甘李药业：9月2日高级管理人员李智减持股份合计1000股
证券之星 · 09-03
甘李药业：9月2日高级管理人员李智减持股份合计1000股
甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）
美股速递 · 09-03
甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）
甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》
智通财经 · 09-03
甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":73.56,"timestamp":1791442800000,"preClose":77.4,"halted":0,"volume":13360295,"delay":0,"changeRate":-0.0496,"floatShares":561000000,"shares":597000000,"eps":1.9244,"marketStatus":"已收盘","change":-3.84,"latestTime":"10-08 15:00:00","open":77.4,"high":78.27,"low":73.2,"amount":997000000,"amplitude":0.0655,"askPrice":73.57,"askSize":3,"bidPrice":73.56,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.9244,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":5,"adr":0,"adjPreClose":77.4,"symbolType":"stock","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":85.14,"lowLimit":69.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597432169,"isCdr":false,"pbRate":3.75,"roa":"--","peRate":38.224901,"roe":"5.15%","epsLYR":1.93,"committee":0.137931,"marketValue":43947000000,"turnoverRate":0.0238,"status":1,"floatMarketCap":41298000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2671019492","title":"甘李药业：9月29日陈伟、邹蓉、都凯、宋维强减持股份合计3.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671019492","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671019492?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:01","pubTimestamp":1790769691,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月30日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月29日公司董事,高级管理人员陈伟、高级管理人员邹蓉、高级管理人员,董事都凯、董事,高级管理人员宋维强共减持公司股份3.5万股，占公司总股本为0.0058%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000034271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671266258","title":"甘李药业（603087）9月28日主力资金净卖出529.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671266258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671266258?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:25","pubTimestamp":1790641516,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，甘李药业报收于73.96元，上涨0.71%，换手率1.69%，成交量9.49万手，成交额7.05亿元。近5日资金流向一览见下表：甘李药业融资融券信息显示，融资方面，当日融资买入5766.53万元，融资偿还7776.01万元，融资净偿还2009.48万元。甘李药业主营业务：胰岛素类似物原料药及注射剂研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670638232","title":"甘李药业：9月24日董事宋维强减持股份合计3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670638232","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670638232?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:01","pubTimestamp":1790596893,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月28日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月24日公司董事,高级管理人员宋维强共减持公司股份3.0万股，占公司总股本为0.005%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1048.48万，融资余额减少；融券净流入4000.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800030212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669230432","title":"甘李药业（603087）9月23日主力资金净买入4477.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669230432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669230432?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:15","pubTimestamp":1790208958,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，甘李药业报收于74.56元，上涨5.47%，换手率2.95%，成交量16.54万手，成交额12.12亿元。近5日资金流向一览见下表：甘李药业融资融券信息显示，融资方面，当日融资买入1.12亿元，融资偿还1.04亿元，融资净买入800.93万元。甘李药业主营业务：胰岛素类似物原料药及注射剂研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810916","title":"9月23日甘李药业涨5.47%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669810916?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:36","pubTimestamp":1790152618,"startTime":"0","endTime":"0","summary":"证券之星消息，9月23日甘李药业涨5.47%，收盘报74.56元，换手率2.95%，成交量16.54万手，成交额12.12亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共31家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4118，较上一交易日下跌0.46%，近一年下跌9.49%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","161726","399441","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669096741","title":"甘李药业涨5.47%，国金证券四周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669096741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669096741?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:36","pubTimestamp":1790152609,"startTime":"0","endTime":"0","summary":"今日甘李药业涨5.47%，收盘报74.56元。2026年8月26日，国金证券研究员甘坛焕,马居东发布了对甘李药业的研报《二季度环比高增，出海及研发持续突破》，该研报对甘李药业给出“买入”评级。维持“买入”评级证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为77.02%。甘李药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163619","title":"甘李药业：9月17日高级管理人员李智减持股份合计2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163619","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669163619?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:02","pubTimestamp":1789992132,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月21日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月17日公司高级管理人员李智共减持公司股份2.0万股，占公司总股本为0.0033%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出2768.81万，融资余额减少；融券净流出2200.0，融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100028835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668417945","title":"甘李药业(603087.SH)：在研药品GLR1075注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668417945","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668417945?lang=zh_cn&edition=full","pubTime":"2026-09-18 15:37","pubTimestamp":1789717057,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)下发的关于在研药品GLR1075注射液的《药物临床试验批准通知书》，经审查，2026年7月3日受理的GLR1075注射液临床试验申请符合药品注册的有关要求，同意本品开展肝硬化腹水低白蛋白血症的临床试验。GLR1075注射液是甘李药业自主研发的重组人白蛋白制剂，属于人源化重组蛋白药物。其活性成分重组人白蛋白与天然人血清白蛋白具有相同的氨基酸序列和相似的空间构象，可发挥白蛋白的核心生理功能，包括纠正胶体渗透压失衡、改善病理微环境等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","PSYK","BMED","603087","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668952566","title":"甘李药业：股价波动受多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2668952566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668952566?lang=zh_cn&edition=full","pubTime":"2026-09-17 15:33","pubTimestamp":1789630399,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业(603087)09月17日在投资者关系平台上答复投资者关心的问题。投资者提问：股价这么剧烈波动，公司依旧不管不问？甘李药业回复：尊敬的投资者您好，股价波动受宏观经济、行业政策、市场情绪等多种因素影响，短期涨跌并不能充分反映公司的长期价值。公司将持续聚焦主业，致力于以扎实的经营业绩回馈广大投资者。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700019023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668523649","title":"甘李药业：公司产品在泰国获得上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668523649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668523649?lang=zh_cn&edition=full","pubTime":"2026-09-17 15:33","pubTimestamp":1789630398,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业09月17日在投资者关系平台上答复投资者关心的问题。股价波动受宏观经济、行业政策、市场情绪等多种因素影响，短期涨跌并不能充分反映公司的长期价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700019022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668952551","title":"甘李药业：本次海外50多亿的订单为协议全周期潜在里程碑与销售分成总额","url":"https://stock-news.laohu8.com/highlight/detail?id=2668952551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668952551?lang=zh_cn&edition=full","pubTime":"2026-09-17 15:33","pubTimestamp":1789630397,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业09月17日在投资者关系平台上答复投资者关心的问题。请问在大盘上涨和利好情况下为何估值这样一般甘李药业回复：尊敬的投资者您好，本次海外50多亿的订单为协议全周期潜在里程碑与销售分成总额，并非当期可确认收入，多数款项需依赖后续临床、获批、商业化等多个节点的实现而兑现，存在不确定性。股价波动受宏观经济、行业政策、市场情绪等多种因素影响，短期涨跌并不能充分反映公司的长期价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700019020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667073085","title":"每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667073085","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667073085?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:48","pubTimestamp":1789235295,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，甘李药业报收于66.34元，较上周的70.1元下跌5.36%。公司公告汇总关于GZC8072片Ⅰ期临床试验完成首例受试者给药的公告甘李药业股份有限公司全资子公司甘李药业山东有限公司自主研发的GZC8072片，于近日在中国成功完成Ⅰ期临床试验首例受试者给药。关于完成工商登记信息变更的公告甘李药业股份有限公司已完成工商登记信息变更，公司总股本和注册资本因2026年限制性股票激励计划630,000股授予登记完成而相应增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149513139","title":"甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1149513139","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149513139?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:01","pubTimestamp":1788958893,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其自主研发的新型超长效口服多肽GLP-1受体激动剂Gzc8072，已在首次人体I期临床研究中完成首例受试者给药。Gzc8072凭借其创新的分子设计，旨在实现每周一次的口服给药方案，从而大幅提升患者用药的便利性与依从性。随着首例受试者的顺利入组，该研究的后续数据读出备受期待，其结果将为Gzc8072的后续临床开发策略提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665632905","title":"甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665632905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665632905?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:57","pubTimestamp":1788861451,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，甘李药业报收于69.39元，较前一交易日上涨0.39%，最新总市值为414.56亿元。该股当日开盘69.2元，最高69.9元，最低68.57元，成交额达3.12亿元，换手率为0.8%。甘李药业股份有限公司全资子公司甘李药业山东有限公司自主研发的GZC8072片，于近日在中国成功完成Ⅰ期临床试验首例受试者给药。该产品已获国家药监局多项临床试验批准，截至2026年6月30日，累计研发投入6,633.26万元。目前全球尚无GLP-1口服周制剂获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397088","title":"甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665397088?lang=zh_cn&edition=full","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","MDTX","603087","BK0239","IBBQ","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331601","title":"甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331601","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664331601?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:01","pubTimestamp":1788523302,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月4日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月3日公司董事李智、董事,高级管理人员宋维强共减持公司股份1.3万股，占公司总股本为0.0022%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出2589.94万，融资余额减少；融券净流入4700.0，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400037763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664996382","title":"甘李药业：高管减持潮背后，财务与转型双重考验显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2664996382","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664996382?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:25","pubTimestamp":1788506700,"startTime":"0","endTime":"0","summary":"胰岛素集采重塑行业格局之后，甘李药业完成管理层迭代，押注 GLP\u001e1 管线，接连签下大额海外授权订单，市场对其转型预期升温。整体来看，甘李药业站在行业转型十字路口，手握大额 BD 利好，但财务质量、高管减持、管线兑现、主业增长多重风险交织。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-04/doc-iniqryew1339260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871740","title":"甘李药业：9月2日高级管理人员李智减持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871740","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664871740?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:01","pubTimestamp":1788436893,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月3日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月2日公司高级管理人员李智共减持公司股份1000.0股，占公司总股本为0.0002%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1790.63万，融资余额减少；融券净流入1000.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300038197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184990997","title":"甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）","url":"https://stock-news.laohu8.com/highlight/detail?id=1184990997","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184990997?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:53","pubTimestamp":1788429200,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其潜在交易总价值最高可达7.26亿欧元。值得注意的是，这一数字尚未将特许权使用费纳入考量范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664270568?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","PSYK","603087","BK0239","MDTX","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791460882296,"stockEarnings":[{"period":"1week","weight":0.0381},{"period":"1month","weight":0.1229},{"period":"3month","weight":0.352},{"period":"6month","weight":0.2492},{"period":"1year","weight":0.0393},{"period":"ytd","weight":0.1589}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"75587人(较上一季度减少7.78%)","perCapita":"7427股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59743万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}